Microbot Medical has secured a non-dilutive NIS2.15m (around $630,000) grant from the Israel Innovation Authority (IIA) to bolster its manufacturing capabilities, as well as progress towards the commercialisation of the Liberty endovascular robotic system.
Intended for endovascular procedures, the single-use surgical robotic system is yet to receive US Food and Drug Administration (FDA) approval.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
IIA recognises Microbot’s recent milestones and the potential impact of the Liberty system.
Factors such as the size of the target market, the competitive edge of a disposable robot, regulatory status, and anticipated healthcare benefits contributed to the grant award.
Microbot Medical’s chief financial officer Rachel Vaknin said: “This non-dilutive grant strengthens our balance sheet and allows us to further enhance our operational readiness plans as we await the FDA’s marketing clearance decision.
“The IIA has been a valued partner supporting the development of the LIBERTY System with prior grants, and this latest award and timing are particularly significant as we believe it reflects high confidence in our ability to scale manufacturing and successfully meet our business objectives.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn April 2025, Microbot unveiled the results of its ACCESS-PVI pivotal study of the Liberty system at the Society of Interventional Radiology’s annual meeting.
Conducted across three US medical centres, the trial demonstrated the feasibility of robotic endovascular procedures with Liberty, minimising radiation exposure for operators.
Key findings from the study include a complete success rate in robotic navigation, zero adverse device events, a 92% relative decrease in radiation exposure for operators, and a median robotic navigation time of three minutes.
In June 2025, Microbot secured a patent from the China National Intellectual Property Administration (CNIPA), marking an advancement in the company’s international intellectual property strategy. The newly granted patent pertains to the robotic control of a surgical tool handle.
Last year, Microbot Medical and Emory University in the US entered an agreement to further explore the autonomous capabilities of the Liberty system.
